Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0018681 (headache)
 56,091 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The diagnostic quality and side effects of Amipaque and Pantopaque as myelographic contrast agents were compared prospectively using the identical protocol in 167 cases (117 Amipaque, 50 Pantopaque). Good ratings were attained in 74% of Amipaque and 76% of Pantopaque examinations. Demonstration of nerve rootlets in the cauda equina and filling of lumbar root sleeves were superior with Amipaque. Amipaque more easily demonstrated the high posterior cervical subarachnoid space and the anterior and posterior margins of the cervical spinal cord. The incidence of postmyelographic headache was 38% with Amipaque and 32% with Pantopaque. Nausea and vomiting were more common with Amipaque. Two patients experienced grand mal seizures after examination sith Amipaque.
 ...
PMID:Contrast agents for myelography: clinical and radiological evaluation of Amipaque and Pantopaque. 10 30

Side effects of metrizamide (Amipaque) and meglumine iocarmate (Dimer-X) were compared in lumbar myelography of 161 patients by a prospective, parallel, interview study. Severe complications were not observed. The percentage pairs of smaller complications were mainly in favour of Dimer-X, but in 2 of the 54 pairs only the difference did raise to a significant level. In one pair there were less symptomless patients after Amipaque-myelography (p less than 0.05) and in another pair the men had more headache after Amipaque-myelography (p less than 0.01). It may be possible to show with larger comparative series, that Amipaque has a tendency to cause more central-subcortical or meningeal-side effects than Dimer-X.
 ...
PMID:[Side effect of metrizamide and meglumine iocarmate in lumbar myelography. A prospective, parallel, interview study (author's transl)]. 14 86

The technique, the quality of the films and the frequency of side effects are evaluated in 100 consecutive cervical myelographies with lumbar injection of metrizamide (Amipaque). The most frequent adverse effects were headache (47%) and nausea and vomiting (27%). EEG disturbances were recorded in 20 per cent. Due to special circumstances grand mal seizures and mental confusion occurred in one patient; this was the only major complication in altogether 260 cervical myelographies with lumbar injection.
 ...
PMID:Cervical myelography with metrizamide using lumbar injection. 29 63

The normal cerebrospinal fluid flow as monitored by serial CT cisternography with metrizamide (Amipaque) is described in 25 individuals. Preliminary gross autoradiography using 131I-labelled metrizamide concur with these CT cisternographic findings indicating that intrathecally introduced metrizamide penetrates the brain substance. Adverse reactions are most prominent during the periods of maximum brain penetration and include headache, nausea, perceptual aberrations, and EEG alterations. The value and diagnostic applications of cerebral and cerebellar penetration of metrizamide are also discussed.
 ...
PMID:Metrizamide brain penetrance. 29 73

A non-ionic water-soluble contrast medium, Amipaque (metrizamide), was studied for use in ventriculography both experimentally and clinically, and identified as having markedly low toxicity. Twenty adult mongrel dogs were injected intraventricularly of intracisternally with 2.0 to 5.0 ml of Amipaque. It was found that Amipaque is safe compared with other water-soluble contrast media, especially relative to epileptogenic effect. The authors also carried out 17 clinical trials of ventriculography using 4.0 to 15.0 ml of Amipaque in 13 neurosurgical patients. There were no troublesome symptoms except for a mild headache as a side-effect in one patient, and Amipaque proved to be a satisfactory diagnostic contrast medium.
 ...
PMID:Ventriculography with non-ionic water-soluble contrast medium, Amipaque (metrizamide). Comparative experimental and clinical studies. 30 Nov 81

The excellently low toxicity of a non-ionic watersoluble contrast medium Amipaque (Metrizamide), which is used for ventriculography, was confirmed by animal experiment and clinical application. In the animal experiment, 20 adult mongrel dogs were used and in each of them 1.5-5.0 ml of Amipaque was injected intraventriculary or intracisternally. As a result, we obtained a finding that the Amipaque is cleary safe compared with other watersoluble contrast media, espcially on epileptogenicity, while having an effect on the definition of picture and the nature of cerebrospinal fluid similar to other watersoluble contrast media. Thereafter, 14 ventriculographies were performed for 11 neurosurgical patients by using 4-10 ml of amipaque. Though one patient complained of a light headache after the examination, in no cases could convulsive complication be observed. The experience of this new medium gave us an impression that ventriculography with watersoluble contrast media will take the place of pneumoventriculography.
 ...
PMID:[Ventriculography with non-ionic water-soluble contrast medium, Amipaque (metrizamide)-experimental and clinical study (author's transl)]. 30 94

Metrizamide is a nonionic water-soluble contrast medium for neuroradiological studies that is less irritating to the nervous system than other water-soluble agents. Studies in adults have shown that metrizamide has advantages over currently available media, but experience with children has been limited. Sixty-two children have had myelography or ventriculography using metrizamide. The children ranged in age from 11 days to 22 years. Technically satisfactory studies were obtained in every patient. No major complications were encountered. Minor side-effects included headache in 11 children (18%), mild nausea or vomiting in 16 children (26%), and fever in 4 children (6%). Seizures did not occur. One infant in the study subsequently died of unrelated problems; there was no evidence of arachnoiditis at postmortem examination. Metrizamide is a safe, effective contrast medium for neuroradiological use in children.
 ...
PMID:Clinical evaluation of metrizamide for neuroradiology in chilren. 31 Feb 77

Radiographic quality as well as adverse effects of intrathecal metrizamide instillation was prospectively investigated in thirty-three clinical cases admitted to the department of neurosurgery, University of Tokyo Hospital, and Kantoh Teishin Hospital. Metrizamide CT cisternography was performed in fifteen cases using in most cases 10 ml of 170 mg I/ml solution through lumbar route. Eleven cases exhibited "normal" pattern CSF circulation and the remaining four, "delayed" pattern. Eight cases (53%) experienced headache, nausea, and/or vomiting several hours after the instillation. All of these belong to the "normal" pattern group. Four cases of "normal" pattern received electroencephalographic examinations before and after metrizamide instillation. Three revealed appearance of negative spike and slow wave burst or sharp waves one to twenty-four hours after the instillation, along with penetration of metrizamide into brain parenchyma. Diagnostic quality was interpreted as "good" in eleven cases. Small acoustic neurinoma, pituitary adenoma, arachnoid cyst, and subdural hygroma were diagnosed among others. Metrizamide ventriculography was done in four cases. No untoward effect of significance was attributed to metrizamide per se. Cervical myelograpy and/or CT myelography was done in fourteen cases using, in most cases, 10 ml of metrizamide 170 mgI/ml. Polytome tomography with metrizamide instillation through lateral cervical puncture was highly diagnostic, whereas, ordinary X-ray with lumbar instillation yielded less satisfactory results. CT myelography in cases of subarachnoid block required good consideration on instillation site and positioning of the patient. Six cases (50%) among twelve cases where metrizamide had run into the cranial cavity experienced headache, nausea, and/or vomiting to a lesser degree than those of cisterno graphy. Metrizamide is the first contrast agent ever made which can be safely introduced into human subarachnoid space, if administered judiciously, nervous. However, metrizamide is weakly toxic to central system and provokes minor untoward effects as well as electroencephalographic abnormalities and, sometimes, clinical convulsive seizure. It would be wiser to restrict the dosage of metrizamide in cisternographic study, expecially in cases of "normal" pattern CSF circulation, to 1.2 gI or 7 ml of 170 mg I/ml solution. Routine use of X-ray cisternography should thus be discouraged because it needs higher concentration of metrizamide in the intracranial cisterns.
 ...
PMID:[Usefulness and adverse effects of intrathecal metrizamide instillation (author's transl)]. 31 37

The technique and results of cerebello-pontine angle cisternography with metrizamide (Amipaque) in 34 patients are reported. Fourteen tumors were diagnosed. The internal auditory canal was normal in 19 patients, and in all of them the facial and statoacoustic nerves were visible. One examination was unsuccessful. No serious complications occurred. Headache was recorded in 76 per cent and transient EEG disturbance in 32 per cent of the patients.
 ...
PMID:Cisternography with metrizamide in cerebellopontine angle tumors. 31 49

The adverse effects following lumbar myelography and ventriculography with meglumine iothalamate (Conray Meglumin), meglumine iocarmate (Dimer-X, Bis-Conray) and metrizamide (Amipaque), and after thoracic and cervical myelography and cisternography with metrizamide are reviewed. In addition to the published material information given to Nyegaard & Co. from several hospitals participating in clinical trials with metrizamide is also reported. The frequency of minor adverse effects (headache, nausea, vomiting) seems to be about the same with all the three water-soluble contrast media. Convulsions, either localized to the lower part of the body or generalized, may be a problem with meglumine iothalamate and meglumine iocarmate, while the epileptogenic effect is markedly lower with metrizamide. With a technique directed towards preventing contrast medium of high concentration from passing intracranially, the frequency of serious adverse effects may be kept at a very low level. Late adverse effects (adhesive arachnoiditis) occurring after all other water-soluble contrast media are a very minor problem after metrizamide. Serious complications have not been recorded following ventriculography and cisternography with metrizamide. Metrizamide is considered to be the water-soluble contrast medium best suited for use in the subarachnoid space and cerebral ventricles.
 ...
PMID:Adverse effects of water-soluble contrast media in myelography, cisternography and ventriculography. A review with special reference to metrizamide. 40 Sep 6


1 2 3 4 Next >>